CIMAvax EGF vaccine was developed by Cuban researchers to treat NSCLC adult patients with stage IIIB/IV after receiving conventional first-line chemotherapy through enhancing the own immune system to produce anti EGF antibodies and decrease the serum EGF. The gene discussed is EGF; the disease is non-small cell lung carcinoma.